Emily R. Levy

3.2k total citations
46 papers, 773 citations indexed

About

Emily R. Levy is a scholar working on Immunology, Oncology and Infectious Diseases. According to data from OpenAlex, Emily R. Levy has authored 46 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 14 papers in Oncology and 12 papers in Infectious Diseases. Recurrent topics in Emily R. Levy's work include Immune Cell Function and Interaction (12 papers), CAR-T cell therapy research (10 papers) and T-cell and B-cell Immunology (9 papers). Emily R. Levy is often cited by papers focused on Immune Cell Function and Interaction (12 papers), CAR-T cell therapy research (10 papers) and T-cell and B-cell Immunology (9 papers). Emily R. Levy collaborates with scholars based in United States, Australia and Sweden. Emily R. Levy's co-authors include Richard Childs, Robert Reger, Mattias Carlsten, Maria Berg, Linhong Li, Madhusudan V. Peshwa, Steven G. DuBois, Rabin Banerjee, Sanjeev Swami and Leslie E. Kahl and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and Cancer Research.

In The Last Decade

Emily R. Levy

43 papers receiving 750 citations

Peers

Countries citing papers authored by Emily R. Levy

Since Specialization

Citations

This map shows the geographic impact of Emily R. Levy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily R. Levy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily R. Levy more than expected).

Fields of papers citing papers by Emily R. Levy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily R. Levy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily R. Levy. The network helps show where Emily R. Levy may publish in the future.

Co-authorship network of co-authors of Emily R. Levy

This figure shows the co-authorship network connecting the top 25 collaborators of Emily R. Levy. A scholar is included among the top collaborators of Emily R. Levy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily R. Levy. Emily R. Levy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disseminated vaccine-strain varicella-zoster virus reactivation in an adolescent with secondary immunodeficiency: a case report and literature review 2024 ·BMC Infectious Diseases ·(unknown), (unknown), Paul J. Galardy, W. Charles Huskins, Emily R. Levy, (unknown), Rana Chakraborty	0
2	Neonatal intestinal colonization of Streptococcus agalactiae and the multiple modes of protection limiting translocation 2024 ·Gut Microbes ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jane E. Brumbaugh, Emily R. Levy, Kathryn A. Knoop	6
3	Infectious diseases and infection control prevention strategies in adult and pediatric population on ECMO 2024 ·Perfusion ·(unknown), Joseph E Marcus, Emily R. Levy, Aditya Shah, Graeme MacLaren, Giles J. Peek	1
4	Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity 2024 ·npj Precision Oncology ·Laura Sanz-Ortega, (unknown), (unknown), Mélanie Lambert, Emily R. Levy, Agneta Andersson, Björn E. Wahlin, Mattias Carlsten	5
5	First-Generation Cephalosporins for Treatment of Acute Hematogenous Osteomyelitis in Children: A Study of Efficacy and Adverse Effects 2023 ·Open Forum Infectious Diseases ·(unknown), (unknown), Emily R. Levy, (unknown), Nipunie Rajapakse, (unknown), (unknown)	0
6	Paediatric safety assessment of BNT162b2 vaccination in a multistate hospital-based electronic health record system in the USA: a retrospective analysis 2023 ·The Lancet Digital Health ·(unknown), Michiel J.M. Niesen, Emily R. Levy, (unknown), Patrick J. Lenehan, (unknown), John C. O’Horo, (unknown), Andrew D. Badley, Venky Soundararajan	10
7	COVID-19 in patients with B cell immune deficiency 2022 ·Journal of Immunological Methods ·Paschalis Vergidis, Emily R. Levy, (unknown), Vivek Iyer, John C. O’Horo, Avni Y. Joshi	1
8	COVID-19: FAQs in Pediatric Cardiac Surgery—A Sequel 2020 ·World Journal for Pediatric and Congenital Heart Surgery ·Emily R. Levy, (unknown), Kathleen Chiotos, Elizabeth H. Stephens, Joseph A. Dearani	1
9	Evaluation of Mannose Binding Lectin Gene Variants in Pediatric Influenza Virus-Related Critical Illness 2019 ·Frontiers in Immunology ·Emily R. Levy, Wai‐Ki Yip, Michael Super, Jill M. Ferdinands, (unknown), Margaret M. Newhams, Yu Zhang, Helen C. Su, Gwenn E. McLaughlin, Anil Sapru, Laura L. Loftis, Scott L. Weiss, Mark W. Hall, Natalie Z. Cvijanovich, Adam J. Schwarz, Keiko M. Tarquinio, Peter M. Mourani, (unknown), (unknown)	5
10	Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X 2019 ·Frontiers in Immunology ·Emily R. Levy, Robert Reger, (unknown), Mélanie Lambert, (unknown), Yvonne Baumer, Mattias Carlsten, Richard Childs	67
11	High-Efficiency Lentiviral Genetic Modification of Primary Human Natural Killer Cells 2017 ·Blood ·(unknown), David Allan, (unknown), Mala Chakraborty, Emily R. Levy, (unknown), Long Chen, (unknown), Georg Aue, Kate Stringaris, Robert Reger, Richard Childs	2
12	Reducing Second Gram-Negative Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell Transplantation Services 2017 ·Infection Control and Hospital Epidemiology ·Rachel L Wattier, Emily R. Levy, Amit J. Sabnis, Christopher C. Dvorak, Andrew D. Auerbach	17
13	Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB–Controlled Oxidative Stress Responses 2016 ·Cancer Research ·Yusuke Shono, Andrea Z. Tuckett, Hsiou‐Chi Liou, Ekaterina Doubrovina, Enrico Derenzini, Samedy Ouk, Jennifer J. Tsai, Odette M. Smith, Emily R. Levy, Fabiana M. Kreines, Carly G.K. Ziegler, (unknown), Mikhail Doubrovin, Glenn Heller, Anas Younes, Richard J. O’Reilly, Marcel R.M. van den Brink, Johannes L. Zakrzewski	33
14	mRNA Transfection to Improve NK Cell Homing to Tumors 2016 ·Methods in molecular biology ·Emily R. Levy, Mattias Carlsten, Richard Childs	17
15	Reminder Cards Improve Physician Documentation of Obesity But Not Obesity Counseling. 2016 ·PubMed ·(unknown), (unknown), Geoffrey Mills, Neesha Patel, (unknown), Victoria Rose, (unknown), (unknown), Emily R. Levy, (unknown), (unknown)	3
16	Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19 2016 ·Frontiers in Immunology ·Mattias Carlsten, Emily R. Levy, (unknown), Linhong Li, Robert Reger, Maria Berg, Madhusudan V. Peshwa, Richard Childs	104
17	Treatment of Pediatric Refractory Coccidioidomycosis With Combination Voriconazole and Caspofungin: A Retrospective Case Series 2013 ·Clinical Infectious Diseases ·Emily R. Levy, John M. McCarty, Andi L. Shane, Peggy Sue Weintrub	30
18	Rates and Appropriateness of Antimicrobial Prescribing at an Academic Children's Hospital, 2007–2010 2012 ·Infection Control and Hospital Epidemiology ·Emily R. Levy, Sanjeev Swami, Steven G. DuBois, (unknown), Rabin Banerjee	57
19	Cell substrate adhesiveness in S49 mouse lymphoma 1980 ·Cell Biology International Reports ·Jacob Hochman, Aviva Katz, Emily R. Levy, (unknown)	3
20	Experience with listeriosis in the new-born. An account of a small epidemic in a nursery ward. 1960 ·PubMed ·Emily R. Levy, E. Nassau	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact